Biogen

Skyclarys approved: HSE to fund Friedreich’s Ataxia drug for Irish patients JOE.ie15:41Skyclarys Biotech Pharma

Friedreich’s ataxia: What is it, and how can Skyclarys help patients? Irish Examiner13:47Skyclarys Biotech Pharma

Will FDA approve Biogen’s promising new treatment for Alzheimer's? The Independent Institute (Weblog)14:13Alzheimer's FDA Pharma

Biogen: Canada's Drug Agency supports public reimbursement of LEQEMBI RTT News06:46Biotech Pharma Canada

Leqembi Iqlik launches in US for early Alzheimer’s PharmaTimes10:51Biotech Pharma Canada

Biogen expands digital strategy with Veeva Vault CRM RTT News03:52Veeva Vault CRM Biotech Pharma

Biogen: 4-year Data support potential disease-modifying effects of zorevunersen RTT News14:04Biotech Pharma Global Health

Latest News

In the last 6 hours

LEQEMBI(R) (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early… JCN Newswire21:05 8-Sept-26

In the last 8 hours

Biogen Must Face Pharmacies' MS Drug Monopoly Suit Law36019:41 8-Sept-26

Yesterday

Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of… JCN Newswire17:00 8-Sept-26

In the last 7 days

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of… Biogen (Press Release)00:37 4-Sept-26

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China Biogen (Press Release)05:06 3-Sept-26

In the last month

Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersen RTT News14:04 1-Sept-26

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational… Biogen (Press Release)12:38 1-Sept-26

Biogen: Canada's Drug Agency Supports Public Reimbursement Of Leqembi RTT News06:46 1-Sept-26

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for… Biogen (Press Release)00:36 1-Sept-26

Why Veeva Systems (VEEV) Is Up 11.6% After Strong Q2, Higher Guidance, and New AI CRM Wins Simply Wall St09:22 30-Aug-26

Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Biogen (Press Release)21:15 27-Aug-26

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the… JCN Newswire20:00 27-Aug-26

Leqembi Iqlik launches in US for early Alzheimer’s PharmaTimes10:51 26-Aug-26

Biogen Expands Digital Strategy With Veeva Vault CRM RTT News03:52 26-Aug-26

Biogen entscheidet sich für Veeva Vault CRM PR Newswire (Press Release)00:37 26-Aug-26

Biogen to Participate in the Wells Fargo 21st Annual Healthcare Conference Biogen (Press Release)21:09 25-Aug-26

Skyclarys approved: HSE to fund Friedreich’s Ataxia drug for Irish patients JOE.ie15:41 25-Aug-26

HSE approves reimbursement of treatment for patients with rare disorder Irish Mirror15:01 25-Aug-26

Veeva Vault CRM seleccionado por Biogen PR Newswire (Press Release)14:41 25-Aug-26

Friedreich’s ataxia: What is it, and how can Skyclarys help patients? Irish Examiner13:47 25-Aug-26

HSE approves Skyclarys funding for Friedreich’s ataxia patients after campaign Irish Examiner12:26 25-Aug-26

Biogen a choisi Veeva Vault CRM PR Newswire (Press Release)12:18 25-Aug-26

Veeva Vault CRM Selected by Biogen PR Newswire (Press Release)12:03 25-Aug-26

Decision due on Skyclarys funding as Biogen reportedly makes lower price offer Irish Examiner11:25 25-Aug-26

Uncertainty over Skyclarys decision as HSE team to meet RTE06:08 25-Aug-26

Talks on Skyclarys have reached a critical point – David Cullinane TD Sinn Féin (Press Release)18:20 24-Aug-26

Biogen And Eisai Launch Leqembi Iqlik Autoinjector For Early Alzheimer's In U.S. RTT News14:02 24-Aug-26

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s… Biogen (Press Release)13:12 24-Aug-26

Leqembi Iqlik®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. … PR Newswire (Press Release)13:04 24-Aug-26

Will FDA Approve Biogen’s Promising New Treatment for Alzheimer’s? The Independent Institute (Weblog)14:13 23-Aug-26

HSE to decide on €280,000-a-year Skyclarys drug for Friedreich’s ataxia Irish Examiner15:13 22-Aug-26

'A problematic child': Ireland's rare drugs record casts doubt over Skyclarys decision Irish Examiner06:43 22-Aug-26

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? Zacks16:24 20-Aug-26

Is Wall Street Bullish or Bearish on Biogen Stock? Barchart13:36 20-Aug-26

Skyclarys maker disputes figures cited in HSE decision not to fund the drug Irish Examiner19:00 18-Aug-26

view more headlines

8 Sept 21:05

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.